Possibilities of Alpha-lipoic Acid Use in Treatment of Diabetes Mellitus Complications in Children and Adolescents

Main Article Content

O.V. Bolshova
O.Ya. Samson

Abstract

The article deals with one of most common complications of diabetes mellitus — diabetic polyneuropathy. It is proved that alpha-lipoic acid is a drug of pathogenetic treatment of such pathology. Through the example of study of 100 patients with diabetes mellitus there was shown the efficacy of alpha-lipoic acid drug Berlithion at diabetic polyneuropathy in children and
adolescents.

Article Details

How to Cite
Bolshova, O., and O. Samson. “Possibilities of Alpha-Lipoic Acid Use in Treatment of Diabetes Mellitus Complications in Children and Adolescents”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), no. 2.42, Mar. 2012, pp. 102-6, doi:10.22141/2224-0721.0.2.42.2012.176864.
Section
Pediatric Endocrinology

References

American Diabetes Association, American Academy of Neurology: Report and recommendations of the San Antonio Conference on Diabetic Neuropathy (Consensus Statement) // Diab. Care. — 1988. — Vol. 11. — P. 592-597.

Boulton A.J.M. et al. Diabetic somatic neuropathies // Diab. Care. — 2004. — Vol. 27. — P. 1458-1486.

Boulton A.J.M. et al. Diabetic neuropathies: a statement by the American Diabetes Association // Diab. Care — 2005. — Vol. 28. — P. 956-962.

Wang Y. et al. Enhanced inflammatory response via activation of NF-kappaB in acute experimental diabetic neuropathy subjected to ischemia-reperfusion injury // J. Neurol. Sci. — 2006. — Vol. 15. — P. 47-52.

Coppini D.V., Bowtell P.A., Weng C. et al. Showing neuropathy is related to increased mortality in diabetic patients: a survival analysis using an accelerated failure time model // J. Clin. Epidemiol. — 2000. — Vol. 53. — P. 519-523.

Dyck P.J., Dyck P.J.B. Diabetic polyneuropathy: section III // Diabetic Neuropathy / Eds. P.J. Dyck, P.K. Thomas. — 2nd ed. — Philadelphia: W.B. Saunders, 1999. — P. 255-278.

Sundkvist G. et al. Sorbitol and myo-inositol levels and morphology of sural nerve in relation to peripheral nerve function and clinical neuropathy in men with diabetic, impaired, and normal glucose tolerance // Diab. Med — 2000. — Vol. 17. — P. 259-268.

Over D.S. et al. Quantitative assessment of diabetic peripheral neuropathy with use of the clanging tuning fork test // Endocr Pract. — 2007. — Vol. 13. — P. 5-10.

Satish K. et al. Role of Aldose Reductase and Oxidative Damage in Diabetes and the Consequent Potential for Therapeutic Options. First published online on April 6, 2005 // Endocrine Reviews doi:10.1210/er. 2004-0028.

Sima A.A.F., Sugimoto K. Experimental diabetic neuropathy: an update // Diabetologia. — Vol. 42. — P. 773-788.

Breqovski V.B. et al. Predictors of alpha-lipoic acid treatment efficacy in diabetic polyneuropathy of the lower limbs // Ter. Arkh. — 2005. — Vol. 77. — P. 15-19.

Jude E.B., Boulton A.J.M. End-stage complications of diabetic neuropathy // Diab. Rev. — 1999. — Vol. 7. — P. 395-410.

Ametov A.S., Barinov A., Dyck P.J. et al. SYDNEY Trial Study Group: The sensory symptoms of diabetic polyneuropathy are improved with a-lipoic acid: the SYDNEY trial // Diab. Care. — 2003. — Vol. 26. — P. 770-776.

Nagamatsu M. Lipoic acid improves distal nerve blood flow, reduces oxidative stress and improves distal nerve conduction in experimental diabetic neuropathy // Diabetes. — 2000. — Vol. 49. — P. 1006-1015.

Ruhnau K.J. et al. Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy // Diab. Med. — 1999. — Vol. 16. — P. 1040-1043.

Tanq J. et al. Alpha-lipoic acid may improve symptomatic diabetic polyneuropathy // Neurologist. — 2007. — Vol. 13. — P. 164-167.

Shaw J.E. et al. Epidemiology of diabetic neuropathy // Textbook of Diabetic Neuropathy / Eds. F.A. Gries, N.E. Cameron, P.A. Low, D. Ziegler. — New York: Thieme, 2003. — P. 64-82

Ziegler D., Hanefeld M., Ruhnau K.J. et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study) // Diabetologia. — 1995. — Vol. 38(12). — P. 1425-1433.

Reljanovic M., Reichel G., Rett K. et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy // Free Radic. Res. — 1999. — Vol. 31(3). — P. 171-179.

Ziegler D., Hanefeld M., Ruhnau K.J. et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy // Diabetes Care. — 1999. — Vol. 22 (8). — P. 1296-1301.

Ziegler D., Schatz H., Conrad F. et al. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie // Diabetes Care. — 1997 Mar. — 20(3). — 369-73.

Ruhnau K.J., Meissner H.P., Finn J.R., Reljanovic M., Lobisch M., Schütte K., Nehrdich D., Tritschler H.J., Mehnert H., Ziegler D. Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy // Diabet Med. — 1999. — Vol. 16(12). — P. 1040-1043.

Ametov A.S., Barinov A., Dyck P. et al. SYDNEY Trial Study Group.The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial // Diabetes Care. — 2003. — Vol. 26 (3). — P. 770-776.

Most read articles by the same author(s)

1 2 > >>